Table 1.
Patient characteristics of all cohorts in high-grade serous ovarian carcinoma
| All cohorts (N = 814) | |||
|---|---|---|---|
| SEV | TCGA | SMC | |
| (N = 394) | (N = 284) | (N = 136) | |
| Number of WSIs | 754 | 516 | 136 |
| Age | 53.9 ± 10.9 | 59.8 ± 11.2 | 56.9 ± 8.7 |
| Stage | |||
| I | 0 (0.0%) | 12 (4.2%) | 12 (8.8%) |
| II | 0 (0.0%) | 24 (8.5%) | 14 (10.3%) |
| III | 214 (54.3%) | 227 (79.9%) | 77 (56.6%) |
| IV | 180 (45.7%) | 20 (7.0%) | 33 (24.3%) |
| Not available | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| BRCA mutation status | |||
| Mutant | 65 (16.5%) | 19 (6.7%) | 28 (20.6%) |
| Wildtype | 148 (37.6%) | 265 (93.3%) | 107 (78.7%) |
| Unknown | 181 (45.9%) | 0 (0.0%) | 1 (0.7%) |
| HRD status (Telli et al.)33 | |||
| Positive | 0 (0.0%) | 153 (55.4%) | 0 (0.0%) |
| Negative | 0 (0.0%) | 114 (41.3%) | 0 (0.0%) |
| Unknown | 0 (0.0%) | 9 (3.3%) | 0 (0.0%) |
| HRD status (Takaya et al.)34 | |||
| Positive | 0 (0.0%) | 140 (49.3%) | 0 (0.0%) |
| Negative | 0 (0.0%) | 139 (48.9%) | 0 (0.0%) |
| Unknown | 0 (0.0%) | 5 (1.8%) | 0 (0.0%) |
| HRD status (Perez-Villatoro et al.)35 | |||
| Positive | 0 (0.0%) | 68 (23.9%) | 0 (0.0%) |
| Negative | 0 (0.0%) | 15 (5.3%) | 0 (0.0%) |
| Not evaluated | 0 (0.0%) | 29 (10.2%) | 0 (0.0%) |
| Undefined | 0 (0.0%) | 172 (60.6%) | 0 (0.0%) |
| Platinum response groups | |||
| Platinum-resistant (PFI < 6 mo) | 73 (18.5%) | 12 (4.2%) | 6 (4.4%) |
| Partially platinum-sensitive (PFI 6–12 mo) | 59 (15.0%) | 47 (16.5%) | 32 (23.5%) |
| Platinum-sensitive (PFI 12–24 mo) | 85 (21.6%) | 128 (45.1%) | 2 (1.5%) |
| Very platinum-sensitive (PFI > 24 mo) | 177 (44.9%) | 97 (34.2%) | 96 (70.6%) |
HRD homologous recombination deficiency, mo months, PFI platinum-free interval, WSIs whole slide images.